Evidence map›Paper›PMID 27352623›Full record

Trial reportJournal of the American Society of Nephrology : JASN2017

Rituximab for Severe Membranous Nephropathy: A 6-Month Trial with Extended Follow-Up.

Karine Dahan, Hanna Debiec, Emmanuelle Plaisier, Marine Cachanado, Alexandra Rousseau, Laura Wakselman, Pierre-Antoine Michel, Fabrice Mihout, Bertrand Dussol, Marie Matignon and 4 more

3 registry-linked trialsOpen access · bronzeAbstract readMulticenter StudyRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Journal of the American Society of Nephrology : JASN, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 3 registered trials, which are not on this map. Cited by 248 papers, 14 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
248citing papers in PubMed, 14 pooled it
22.7field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT01508468 phase3completednot on this map

Prospective Randomized Multicentric Open Label Study to Evaluate Rituximab Treatment for Idiopathic Membranous Nephropathy (IMN)

TypeinterventionalSponsorAssistance Publique - Hôpitaux de ParisRan2012 to 2016Enrolled80ConditionsIdiopathic Membranous NephropathyArmssymptomatic treatment (Converting Enzyme inhibitor, Angiotensin II, Anti-renin, Aldosterone antagonist diuretic, Beta blocker, Calcium inhibitor, statin), experimental (Non Immunosuppressive Symptomatic Treatment (NIST) and Rituximab)
NCT03880643 completednot on this mapstarted 2018, after this paper: background citation

Efficacy and Safety of Rituximab in Patients With Refractory Primary Membranous Nephropathy

TypeobservationalSponsorIstanbul UniversityRan2018 to 2019Enrolled36ConditionsGlomerulonephritis, Membranous
NCT04745728 phase3recruitingnot on this mapstarted 2021, after this paper: background citation

Different Immunosuppressive Treatment in Idiopathic Membranous Nephropathy: a Prospective Cohort

TypeinterventionalSponsorPeking Union Medical College HospitalRan2021 to 2029Enrolled200ConditionsIdiopathic Membranous NephropathyArmsPrednisone, Cyclophosphamide, Rituximab
3 · Its place in the literature

Who cites it

248 citing papers in PubMed, 14 syntheses or guidelines pooled it, 412 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Pooled it
  8. Pooled it
  9. Pooled it
  10. Pooled it
  11. Pooled it
  12. Pooled it
  13. Pooled it
  14. Pooled it
  15. Trial
  16. Trial
  17. Trial
  18. Trial
  19. Article
  20. Article

188 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 5 institutions in 1 country.

Karine DahanDepartment of Nephrology and Dialysis, Assistance Publique Hôpitaux de Paris, Hôpital Tenon, Paris, France; karine.dahan@aphp.fr pierre.ronco@upmc.fr.
Hanna DebiecSorbonne Universités, Université Pierre et Marie Curie Paris 06, Paris, France.
Emmanuelle PlaisierDepartment of Nephrology and Dialysis, Assistance Publique Hôpitaux de Paris, Hôpital Tenon, Paris, France.
Marine CachanadoDepartment of Clinical Pharmacology and Unité de Recherche Clinique, Assistance Publique Hôpitaux de Paris, Hôpital Saint Antoine, Paris, France.
Alexandra RousseauDepartment of Clinical Pharmacology and Unité de Recherche Clinique, Assistance Publique Hôpitaux de Paris, Hôpital Saint Antoine, Paris, France.
Laura WakselmanDepartment of Clinical Pharmacology and Unité de Recherche Clinique, Assistance Publique Hôpitaux de Paris, Hôpital Saint Antoine, Paris, France.
Pierre-Antoine MichelDepartment of Nephrology and Dialysis, Assistance Publique Hôpitaux de Paris, Hôpital Tenon, Paris, France.
Fabrice MihoutDepartment of Nephrology and Dialysis, Assistance Publique Hôpitaux de Paris, Hôpital Tenon, Paris, France.
Bertrand DussolDepartment of Nephrology and Transplantation, Assistance Publique-Hôpitaux de Marseille, Hôpital de la Timone, Marseille, France.
Marie MatignonDepartment of Nephrology and Transplantation, Assistance Publique Hôpitaux de Paris, Hôpital Henri Mondor, Creteil, France; and.
Christiane MoussonDepartment of Nephrology and Transplantation, Centre Hospitalier Universitaire, Dijon, France.
Tabassome SimonDepartment of Clinical Pharmacology and Unité de Recherche Clinique, Assistance Publique Hôpitaux de Paris, Hôpital Saint Antoine, Paris, France.
Pierre RoncoDepartment of Nephrology and Dialysis, Assistance Publique Hôpitaux de Paris, Hôpital Tenon, Paris, France; karine.dahan@aphp.fr pierre.ronco@upmc.fr.
GEMRITUX Study Group
Sorbonne Université · FRInserm · FRAssistance Publique Hôpitaux de Marseille · FRAssistance Publique – Hôpitaux de Paris · FRCHU Dijon Bourgogne · FR

Funding

European Research Council 322947
6 · The paper itself

Abstract

Randomized trials of rituximab in primary membranous nephropathy (PMN) have not been conducted. We undertook a multicenter, randomized, controlled trial at 31 French hospitals (NCT01508468). Patients with biopsy-proven PMN and nephrotic syndrome after 6 months of nonimmunosuppressive antiproteinuric treatment (NIAT) were randomly assigned to 6-month therapy with NIAT and 375 mg/m

Indexed as

FemaleFollow-Up StudiesGlomerulonephritis, MembranousHumansImmunologic FactorsMaleMiddle AgedRituximabSeverity of Illness IndexTime FactorsImmunologic FactorsRituximabanti-PLA2R antibodyanti-THSD7A antibodyidiopathic membranous nephropathyrandomized controlled trialrituximabsevere adverse event

Identifiers

PMID27352623
PMCPMC5198292
OpenAlexW2470335436

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.